[Synthesis of platelet activation factor analogs].

Novel structural analogues of the platelet activating factor (PAF), rac-1-octadecyl-2-allyl-glycerol-3-phosphocholine and rac-1-octadecyl-2-allyl-1-thioglycerol-3-phosphocholine , have been synthesized. The phospholipids obtained showed neither PAF-agonistic nor PAF-antagonistic activity at the concentration of 10(-5) to 10(-7) M.

[The anti-inflammatory activity of structural analogs of the platelet-activating factor].

The pro- and anti-inflammatory activity of new structural analogues of the platelet-activating factor (PAF) was studied. It was found that three PAF analogues inhibit PAF-induced rat paw edema in a dose-dependent manner. The anti-inflammatory activity of one of the PAF analogues upon PAF- or carrageenan-induced inflammation was comparable or in some extent exceeded that of dexamethasone.

[Mechanism of suppression of human peripheral blood lymphocyte proliferation by platelet activation factor].

The influence of the phospholipid platelet activation factor (PAF) was studied on PHA-stimulated proliferation of peripheral blood lymphocytes in patients with bronchial asthma and normal subjects. It was found that influencing on the whole population of lymphocytes PAF suppressed proliferation mainly of T-cells. Besides, the influence of PAF on lymphocyte proliferation seemed to be mediated by monocytes since removal of monocytes from the whole population of mononuclear cells abolished the suppression of lymphocyte proliferation induced by PHA.

[New types of polymerizable phosphatidylcholines, synthesis and properties].

Phosphatidylcholines bearing 11-methacryloylaminoundecanoyl or 12-keto-10-octadecanoyl residues were synthesized. Both phosphatidylcholines are easily polymerized under UV irradiation. The second phospholipid produces liposomes which, after polymerization, acquire an increased stability to deteriorating factors (organic solvents, detergents and human plasma).